To Evaluate the Performance and Efficiency of Robotic Surgery in Children and Adults (PECRoP)

August 6, 2026 updated by: Assistance Publique - Hôpitaux de Paris

Robotic minimally invasive surgery has been rapidly adopted for a wide variety of surgical procedures in adult patients across a broad spectrum of surgical specialties. This has occurred despite the high costs and uncertain benefits of surgical robots.

In contrast, Children's Hospitals and pediatric surgical disciplines have been much slower to embrace the surgical robot. Many children's hospitals do not even possess a surgical robot, and many of those that do borrow them from the adult operating room within the same medical facility.

Since the first case of robotic minimally invasive surgery in children in 2000, robotic procedures have been slowly adopted by select pediatric surgical specialists.

Advocates of robotic minimally invasive surgical systems add many useful features that include improved dexterity, motion scaling, tremor filtration, greater optical magnification (up to 10x), stereoscopic vision, operator-controlled camera movement, and the elimination of the fulcrum effect when compared to conventional laparoscopy. The wristed laparoscopic instruments used in robotic surgery provide seven degrees of freedom.

For the surgeon, these features may allow for more precise dissection with increased magnification and visibility. The intuitive controls of the robot are purported as providing the ability to perform laparoscopic procedures in an "open" fashion. In pediatric surgical procedures, these technical abilities may have the potential to surpass the physical capabilities of human performance in the tight operative fields encountered in children.

This study aims to evaluate the clinical safety, effectiveness, and cost-effectiveness of robot-assisted minimally invasive surgery in both pediatric and adult patients. Robotic surgery was developed to overcome key limitations of conventional laparoscopy, including 2D visualization, limited instrument mobility, poor ergonomics, and long learning curves. The trial will assess clinical outcomes, postoperative pain, length of stay, return to daily activities, access to minimally invasive surgery, and the impact of robotic surgery on surgical training. Specific indications, such as pyeloplasty, will also be compared with open and conventional laparoscopic approaches.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Minimally invasive surgery (MIS) has transformed surgical practice since the 1980s, offering reduced postoperative pain, shorter hospitalization, faster recovery, and improved cosmetic outcomes. However, conventional laparoscopy is limited by rigid instruments, 2D imaging, non-intuitive motion, and challenging ergonomics, resulting in long learning curves, especially in pediatric surgery where operative spaces are smaller.

Robot-assisted surgery, introduced in 1999 with the Da Vinci system, was designed to overcome these limitations by providing 3D high-definition visualization, articulated instruments with seven degrees of freedom, tremor filtration, intuitive movements, surgeon-controlled camera operation, and improved ergonomics. Its dual-console configuration also enhances surgical training.

Despite widespread adoption in adults, pediatric use remains limited. This multicenter study will evaluate robot-assisted surgery across several specialties (urology, gynecology, visceral surgery, thoracic surgery, pediatric surgery, and ENT), in accordance with CE-marked indications.

The study will assess:

clinical outcomes and quality of life, postoperative pain, length of stay, and return to daily activities, access to MIS for patients with comorbidities or complex multidisciplinary needs, reduction of the learning curve compared with laparoscopy, benefits for resident and fellow training, and, for pyeloplasty, comparison with open and laparoscopic techniques. Interim analyses will be performed and may generate hypotheses for future research.

Study Type

Observational

Enrollment (Estimated)

16000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Paris
      • Paris, Paris, France, 75015
        • Recruiting
        • Hôpital Necker -Enfants Malades
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

all patients operated in surgery department participating of the study with indication of robot in the routine care (all specialities)

Description

Inclusion Criteria :

  • child or adult
  • with an indication for a robotic surgery
  • non-opposition of patient or non-opposition of parents for minor patient

Exclusion Criteria :

  • anatomic or anesthetic contraindication for the mini-invasive surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Other

Cohorts and Interventions

Group / Cohort
patient group
Surgery with robot - all patients operated in surgery department with indication of robot in the routine care (all specialities).
control group
Retroperitoneal coelioscopy - patient operated for pyeloplasty - only for pediatry

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Per and post-surgery complication
Time Frame: 6 months
per and post-surgery complication (Clavien-Dindo score)
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Post-surgery pain with analgesic prescription
Time Frame: 6 months
6 months
Resection quality (R0) of oncologic surgery
Time Frame: 6 months
6 months
Functional results according to the surgery indication
Time Frame: 6 months
6 months
Frequency and percentage of intervention with robot in each speciality
Time Frame: 6 months
6 months
Duration of activity of the operating block
Time Frame: 6 months
6 months
Average duration of anaesthesia
Time Frame: 6 months
6 months
Average duration of robotic surgery and docking
Time Frame: 6 months
6 months
Duration of intervention by speciality (learning curve)
Time Frame: 6 months
6 months
Frequency and percentage of conversion to open-procedure
Time Frame: 6 months
6 months
Post surgery pain (Evendol pain scale)
Time Frame: 6 months
6 months
Prescription of analgesic
Time Frame: 6 months
6 months
Duration of hospitalization
Time Frame: 6 months
6 months
Cost of robotic surgery by indication, tools and supplies
Time Frame: 6 months
6 months
Duration of post surgery work stoppage (activ patient)
Time Frame: 6 months
6 months
Duration before returning to normal activity (other patient)
Time Frame: 6 months
6 months
Difference in average costs per patients (in €) divided by the difference in post operative complications using the Clavien Dindo scale
Time Frame: 6 months
6 months
Quality of life (SF-36)
Time Frame: At the inclusion visit (baseline) and 6 months
36-items Short Form health survey
At the inclusion visit (baseline) and 6 months
Health survey (EQ-5D-5L)
Time Frame: At the inclusion visit (baseline) and 6 months
Each dimension in the EQ-5D-5L has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5)
At the inclusion visit (baseline) and 6 months
The Saint-George's hospital Respiratory Questionnaire (SGRQ)
Time Frame: At the inclusion visit (baseline) and 6 months
0 indicates best health and 100 indicates worst health
At the inclusion visit (baseline) and 6 months
Patient Global Impression of Improvement (PGI-I)
Time Frame: At the inclusion visit (baseline) and 6 months
1-question assessment designed to evaluate the patient's impression of improvement since surgery- PGI-I score: 1 = very much better; 2 = much better; 3 = a little better; 4 = no change; 5 = a little worse; 6 = much worse; 7 = very much worse
At the inclusion visit (baseline) and 6 months
Female Sexual Function Index (FSFI)
Time Frame: At the inclusion visit (baseline) and 6 months
The FSFI is a validated 19-item self-administered questionnaire assessing female sexual function across six domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) during the previous 4 weeks. Domain scores are weighted according to the FSFI scoring algorithm and summed to generate a total score ranging from 2 to 36, with higher scores indicating better sexual function.
At the inclusion visit (baseline) and 6 months
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire-12 (PISQ-12)
Time Frame: At the inclusion visit (baseline) and 6 months
The PISQ-12 is a validated, disease-specific, self-administered questionnaire designed to assess sexual function in women with pelvic organ prolapse and/or urinary incontinence. The questionnaire consists of 12 items evaluating three domains: behavioral-emotive aspects, physical factors, and partner-related factors affecting sexual function. Responses are summed to generate a total score, with higher scores indicating better sexual function.
At the inclusion visit (baseline) and 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Thomas BLANC, MD; PhD, Assistance Publique - Hôpitaux de Paris
  • Study Chair: Morgane ROUPRET, MD, PhD, Assistance Publique - Hôpitaux de Paris

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 28, 2018

Primary Completion (Estimated)

August 1, 2029

Study Completion (Estimated)

August 1, 2029

Study Registration Dates

First Submitted

July 24, 2017

First Submitted That Met QC Criteria

September 4, 2017

First Posted (Actual)

September 6, 2017

Study Record Updates

Last Update Posted (Actual)

August 10, 2026

Last Update Submitted That Met QC Criteria

August 6, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • NI16026J
  • 2017-A01507-46 (Other Identifier: IDRCB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe